NCT00451958 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 125
- group Id
- BG001
- value
- 126
- group Id
- BG002
- value
- 69
- group Id
- BG003
- value
- 65
- group Id
- BG004
- value
- 385
- units
- Participants
- groups
- description
- The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
- id
- BG000
- title
- Degarelix 80 mg / Degarelix 80 mg
- description
- The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days. Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.
- id
- BG001
- title
- Degarelix 160 mg / Degarelix 160 mg
- description
- During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year. Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study. Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.
- id
- BG002
- title
- Leuprolide 7.5 mg / Degarelix 80 mg
- description
- During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year. Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study. Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.
- id
- BG003
- title
- Leuprolide 7.5 mg / Degarelix 160 mg
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 7.62
- value
- 70.1
- group Id
- BG001
- spread
- 8.25
- value
- 71.1
- group Id
- BG002
- spread
- 9.46
- value
- 72.4
- group Id
- BG003
- spread
- 8.24
- value
- 71.4
- group Id
- BG004
- spread
- 8.29
- value
- 71.1
- description
- CS21A intention-to-treat (ITT) population.
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Female
- measurements
- group Id
- BG000
- value
- 125
- group Id
- BG001
- value
- 126
- group Id
- BG002
- value
- 69
- group Id
- BG003
- value
- 65
- group Id
- BG004
- value
- 385
- title
- Male
- description
- CS21A ITT population.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 48
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 26
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 37
- title
- Czech Republic
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 49
- title
- Mexico
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 18
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 31
- title
- Ukraine
- categories
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 15
- group Id
- BG004
- value
- 106
- title
- Romania
- categories
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 64
- title
- Russian Federation
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 3
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- title
- United Kingdom
- description
- CS21A ITT population.
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.6
- value
- 78.4
- group Id
- BG001
- spread
- 13.4
- value
- 79.2
- group Id
- BG002
- spread
- 11.3
- value
- 78.7
- group Id
- BG003
- spread
- 12.1
- value
- 80.0
- group Id
- BG004
- spread
- 12.5
- value
- 79.0
- description
- CS21A ITT population.
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Body Weight
- unit Of Measure
- kilogram
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 3.92
- value
- 26.4
- group Id
- BG001
- spread
- 3.79
- value
- 26.9
- group Id
- BG002
- spread
- 3.94
- value
- 26.9
- group Id
- BG003
- spread
- 3.67
- value
- 27.1
- group Id
- BG004
- spread
- 3.84
- value
- 26.8
- description
- CS21A ITT population.
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Body Mass Index
- unit Of Measure
- kilogram per square meter
- classes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 51
- title
- Gleason Score 2-4
- categories
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 124
- title
- Gleason Score 5-6
- categories
- measurements
- group Id
- BG000
- value
- 73
- group Id
- BG001
- value
- 63
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 36
- group Id
- BG004
- value
- 208
- title
- Gleason Score 7-10
- description
- CS21A ITT population. The Gleason Score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10, with low numbers being the least aggressive and 10 being the most aggressive. Two of the participants did not have a Gleason Score at Baseline.
- param Type
- NUMBER
- title
- Gleason Score
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 19
- group Id
- BG004
- value
- 114
- title
- Localised
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 24
- group Id
- BG004
- value
- 132
- title
- Locally advanced
- categories
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 75
- title
- Metastatic
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 64
- title
- Not classifiable
- description
- CS21A ITT population. Prostate cancer stage was classified according to the Tumor, Nodes, and Metastatic (TNM) scale to describe the extent of cancer. Localized refers to tumors without involvement of lymph nodes or metastasis. Advanced localized can be larger tumors that may involve the lymph nodes but no metastasis. Metastatic are more advanced cancers that are spreading beyond the original tumor.
- param Type
- NUMBER
- title
- Stage of Prostate Cancer
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 1.28
- upper Limit
- 10.6
- value
- 4.63
- group Id
- BG001
- lower Limit
- 0.55
- upper Limit
- 10.6
- value
- 4.02
- group Id
- BG002
- lower Limit
- 1.34
- upper Limit
- 12.5
- value
- 4.32
- group Id
- BG003
- lower Limit
- 0.37
- upper Limit
- 8.00
- value
- 3.51
- group Id
- BG004
- lower Limit
- 0.37
- upper Limit
- 12.5
- value
- 4.23
- description
- CS21A ITT population.
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Serum Testosterone Levels
- unit Of Measure
- nanograms per milliliter
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 1.70
- upper Limit
- 3187
- value
- 22.2
- group Id
- BG001
- lower Limit
- 1.50
- upper Limit
- 4902
- value
- 22.5
- group Id
- BG002
- lower Limit
- 1.60
- upper Limit
- 2112
- value
- 25.5
- group Id
- BG003
- lower Limit
- 1.60
- upper Limit
- 10952
- value
- 14.0
- group Id
- BG004
- lower Limit
- 1.50
- upper Limit
- 10952
- value
- 21.0
- description
- CS21A ITT population.
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Serum Prostate-Specific Antigen (PSA) Levels
- unit Of Measure
- nanograms per milliliter
- population Description
- CS21A intention-to-treat (ITT) population.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 125
- group Id
- BG001
- value
- 126
- group Id
- BG002
- value
- 69
- group Id
- BG003
- value
- 65
- group Id
- BG004
- value
- 385
- units
- Participants
- groups
- description
- The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
- id
- BG000
- title
- Degarelix 80 mg / Degarelix 80 mg
- description
- The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days. Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.
- id
- BG001
- title
- Degarelix 160 mg / Degarelix 160 mg
- description
- During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year. Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study. Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.
- id
- BG002
- title
- Leuprolide 7.5 mg / Degarelix 80 mg
- description
- During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year. Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study. Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.
- id
- BG003
- title
- Leuprolide 7.5 mg / Degarelix 160 mg
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 7.62
- value
- 70.1
- group Id
- BG001
- spread
- 8.25
- value
- 71.1
- group Id
- BG002
- spread
- 9.46
- value
- 72.4
- group Id
- BG003
- spread
- 8.24
- value
- 71.4
- group Id
- BG004
- spread
- 8.29
- value
- 71.1
- description
- CS21A intention-to-treat (ITT) population.
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Female
- measurements
- group Id
- BG000
- value
- 125
- group Id
- BG001
- value
- 126
- group Id
- BG002
- value
- 69
- group Id
- BG003
- value
- 65
- group Id
- BG004
- value
- 385
- title
- Male
- description
- CS21A ITT population.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 48
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 26
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 37
- title
- Czech Republic
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 49
- title
- Mexico
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 18
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 31
- title
- Ukraine
- categories
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 15
- group Id
- BG004
- value
- 106
- title
- Romania
- categories
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 64
- title
- Russian Federation
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 3
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- title
- United Kingdom
- description
- CS21A ITT population.
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.6
- value
- 78.4
- group Id
- BG001
- spread
- 13.4
- value
- 79.2
- group Id
- BG002
- spread
- 11.3
- value
- 78.7
- group Id
- BG003
- spread
- 12.1
- value
- 80.0
- group Id
- BG004
- spread
- 12.5
- value
- 79.0
- description
- CS21A ITT population.
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Body Weight
- unit Of Measure
- kilogram
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 3.92
- value
- 26.4
- group Id
- BG001
- spread
- 3.79
- value
- 26.9
- group Id
- BG002
- spread
- 3.94
- value
- 26.9
- group Id
- BG003
- spread
- 3.67
- value
- 27.1
- group Id
- BG004
- spread
- 3.84
- value
- 26.8
- description
- CS21A ITT population.
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Body Mass Index
- unit Of Measure
- kilogram per square meter
- classes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 51
- title
- Gleason Score 2-4
- categories
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 124
- title
- Gleason Score 5-6
- categories
- measurements
- group Id
- BG000
- value
- 73
- group Id
- BG001
- value
- 63
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 36
- group Id
- BG004
- value
- 208
- title
- Gleason Score 7-10
- description
- CS21A ITT population. The Gleason Score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10, with low numbers being the least aggressive and 10 being the most aggressive. Two of the participants did not have a Gleason Score at Baseline.
- param Type
- NUMBER
- title
- Gleason Score
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 19
- group Id
- BG004
- value
- 114
- title
- Localised
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 24
- group Id
- BG004
- value
- 132
- title
- Locally advanced
- categories
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 75
- title
- Metastatic
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 64
- title
- Not classifiable
- description
- CS21A ITT population. Prostate cancer stage was classified according to the Tumor, Nodes, and Metastatic (TNM) scale to describe the extent of cancer. Localized refers to tumors without involvement of lymph nodes or metastasis. Advanced localized can be larger tumors that may involve the lymph nodes but no metastasis. Metastatic are more advanced cancers that are spreading beyond the original tumor.
- param Type
- NUMBER
- title
- Stage of Prostate Cancer
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 1.28
- upper Limit
- 10.6
- value
- 4.63
- group Id
- BG001
- lower Limit
- 0.55
- upper Limit
- 10.6
- value
- 4.02
- group Id
- BG002
- lower Limit
- 1.34
- upper Limit
- 12.5
- value
- 4.32
- group Id
- BG003
- lower Limit
- 0.37
- upper Limit
- 8.00
- value
- 3.51
- group Id
- BG004
- lower Limit
- 0.37
- upper Limit
- 12.5
- value
- 4.23
- description
- CS21A ITT population.
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Serum Testosterone Levels
- unit Of Measure
- nanograms per milliliter
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 1.70
- upper Limit
- 3187
- value
- 22.2
- group Id
- BG001
- lower Limit
- 1.50
- upper Limit
- 4902
- value
- 22.5
- group Id
- BG002
- lower Limit
- 1.60
- upper Limit
- 2112
- value
- 25.5
- group Id
- BG003
- lower Limit
- 1.60
- upper Limit
- 10952
- value
- 14.0
- group Id
- BG004
- lower Limit
- 1.50
- upper Limit
- 10952
- value
- 21.0
- description
- CS21A ITT population.
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Serum Prostate-Specific Antigen (PSA) Levels
- unit Of Measure
- nanograms per milliliter
- population Description
- CS21A intention-to-treat (ITT) population.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle